White House Launches TrumpRx; Pfizer Commits $70B

The White House announced TrumpRx, a government-operated direct-to-consumer website, and said Pfizer is the first drugmaker to sign on, committing roughly $70 billion to U.S. manufacturing and offering steep discounts on many medicines (examples cited include Duavee, Eucrisa and Toviaz). Pfizer CEO Albert Bourla joined HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz at the announcement, and officials described the program as delivering “most favored nation” prices to Medicaid enrollees and cash buyers while touting tariff suspensions and other incentives for manufacturers. Details remain sparse and policy experts say the practical impact is unclear because insured patients generally pay negotiated rates and many Medicaid enrollees already have low out‑of‑pocket costs. Critics say some of the administration’s headline claims about price cuts appear exaggerated and note the initiative follows prior White House pressure on drugmakers. Officials said additional pharmaceutical deals are expected as analysts assess effects on budgets, access and research-and-development incentives.